- Home
- AKBA vs BCML Comparison
AKBA vs BCML Comparison
Compare AKBA & BCML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- BCML
- Stock Information
- Founded
- AKBA 2007
- BCML 2004
- Country
- AKBA United States
- BCML United States
- Employees
- AKBA N/A
- BCML N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- BCML Major Banks
- Sector
- AKBA Health Care
- BCML Finance
- Exchange
- AKBA Nasdaq
- BCML Nasdaq
- Market Cap
- AKBA 336.2M
- BCML 279.0M
- IPO Year
- AKBA 2014
- BCML N/A
- Fundamental
- Price
- AKBA $1.93
- BCML $25.72
- Analyst Decision
- AKBA Strong Buy
- BCML
- Analyst Count
- AKBA 3
- BCML 0
- Target Price
- AKBA $6.50
- BCML N/A
- AVG Volume (30 Days)
- AKBA 6.1M
- BCML 18.6K
- Earning Date
- AKBA 05-08-2025
- BCML 04-17-2025
- Dividend Yield
- AKBA N/A
- BCML 2.32%
- EPS Growth
- AKBA N/A
- BCML N/A
- EPS
- AKBA N/A
- BCML 2.10
- Revenue
- AKBA $160,180,000.00
- BCML $96,253,000.00
- Revenue This Year
- AKBA $23.40
- BCML $3.69
- Revenue Next Year
- AKBA $58.44
- BCML $6.08
- P/E Ratio
- AKBA N/A
- BCML $12.19
- Revenue Growth
- AKBA N/A
- BCML N/A
- 52 Week Low
- AKBA $0.80
- BCML $18.54
- 52 Week High
- AKBA $2.89
- BCML $30.13
- Technical
- Relative Strength Index (RSI)
- AKBA 46.74
- BCML 48.14
- Support Level
- AKBA $1.83
- BCML $24.80
- Resistance Level
- AKBA $1.99
- BCML $26.34
- Average True Range (ATR)
- AKBA 0.19
- BCML 0.80
- MACD
- AKBA -0.03
- BCML 0.11
- Stochastic Oscillator
- AKBA 15.42
- BCML 68.69
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About BCML BayCom Corp
BayCom Corp is a bank holding company for United Business Bank. It provides a broad range of financial services to businesses and business owners as well as individuals through its full-service branches and loan production office. The company targets its services to small and medium-sized businesses, professional firms, real estate professionals, nonprofit businesses, labor unions, and related nonprofit entities and businesses and individual consumers. Its products and services include deposit products, personal accounts, loans, online banking, cash management, and business savings services.